抄録
Expanded efforts in drug discovery have not resulted in a parallel increase in the number of safe marketed drugs. Drug-induced cardiotoxicity and hepatotoxicity continue to be major hurdles requiring new methods to identify unsafe compounds earlier in the pipeline and to better manage patient care. A systems biology approach using genomics, metabolomics, proteomics, epigenomics and bioinformatics coupled with in vitro and in vivo methods is beginning to make progress that might improve compound selection and empower personalized (precision) medicine. Examples to be presented include translational work being done in doxorubicin-mediated cardiomyopathy and acetaminophen (paracetamol) induced hepatotoxicity in rodents and humans.
